Daniel Spratt News Today

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Daniel Spratt, MD, discusses the integration of metastasis-directed therapy and hypofractionation in prostate cancer.

Daniel Spratt, MD, discusses the use of radiation therapy in low- and high-risk prostate cancer.

A high impact study led by Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety

Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs.

ArteraAI intended to improve risk stratification or prognostication over standard clinical and pathologic tools and spare men unnecessary treatment.

Its recommended that you consider getting screened once you reach your 40s, which gives you the best chance of getting treated early.

Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.

Daniel Spratt, MD, discusses research findings that have delineated the optimal sequencing of radiation therapy and hormone therapy for patients with prostate cancer.